Human monoclonals from antigen-specific selection of B-lymphocytes and transformation by EBV Academic Article Article uri icon


MeSH Major

  • Kruppel-Like Transcription Factors
  • Lymphoma, B-Cell, Marginal Zone
  • Mutation
  • Splenic Neoplasms


  • Hybridoma technology has made it possible to prepare monoclonal antibodies with the use of murine lymphocytes. Attempts to extend this technology to the human level, however, have met with difficulties. A method has been developed for making human monoclonal antibodies of predetermined specificity. Biotinylated antigens (human thyroglobulin or tetanus toxoid) were incubated with human B lymphocytes from peripheral blood. The lymphocytes to which the antigens bound were selected by fluorescence-activated cell sorting. Positively selected (high fluorescence) and negatively selected (low fluorescence) cells were then transformed with Epstein-Barr virus (EBV) and grown in microculture wells. All wells from the positively selected fraction produced antigen-specific antibody (95 to 1800 nanogram-equivalents per milliliter), whereas fewer than 6% of the wells from negatively selected fraction made any detectable antibody (less than 10 nanogram-equivalents per milliliter). When the positively selected EBV-transformed cells were cultured in limiting dilution, clones were obtained that made antigen-specific monoclonal antibodies. By this method, monoclonal antibodies to both foreign antigens and autoantigens can be prepared from the normal human B-cell repertoire.

publication date

  • December 1986



  • Academic Article


Digital Object Identifier (DOI)

  • 10.1126/science.3020687

PubMed ID

  • 3020687

Additional Document Info

start page

  • 476

end page

  • 9


  • 234


  • 4775